Faruqi & Faruqi, LLP Is Seeking More Cash For The Shareholders Of MAP Pharmaceuticals, Inc. (MAPP)

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of MAP Pharmaceuticals, Inc. (“MAP” or the “Company”) (NasdaqGS: MAPP) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Allergan Inc. (NYSE: AGN) in an all-cash deal valued at approximately $958 million. Under the terms of the proposed transaction, MAP’s stockholders will receive $25 in cash for each share of MAP’s common stock they own. The proposed transaction is structured as a tender offer and may be effectuated without a shareholder vote.

Request more information now by clicking here: www.faruqilaw.com/MAP . There is no cost or obligation to you.

The investigation focuses on whether MAP’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of MAP’s shareholders.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.

If you own common stock in MAP and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/MAP or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.

Copyright Business Wire 2010

If you liked this article you might like

Allergan's Healthy Prospects

Allergan's Healthy Prospects

Cramer's 6 Stocks in 60 Seconds: SNV TXN UL CREE MAPP KBH (Update 1)

Cramer's 6 Stocks in 60 Seconds: SNV TXN UL CREE MAPP KBH (Update 1)

2013 FDA Drug Approval Decision Calendar

2013 FDA Drug Approval Decision Calendar

Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma

Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma

MAP Pharma's Awkward FDA Silence

MAP Pharma's Awkward FDA Silence